Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Anatara Lifesciences Ltd ( (AU:ANR) ) is now available.
Anatara Lifesciences announced progress in their GaRP-IBS clinical trial and anti-obesity project. The GaRP-IBS trial is nearing completion of its second stage, with headline analysis expected in March 2025. The trial, which targets IBS symptoms, has paused recruitment to assess initial results. Meanwhile, ethics approval has been granted for pre-clinical studies in the anti-obesity project, aimed at developing an oral medication for weight control, indicating the company’s strategic focus on expanding its product pipeline.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a developer of evidence-based, innovative products focused on addressing significant unmet needs in human health, particularly conditions involving the complexity of the gastrointestinal tract (GIT). The company aims to create treatments for digestive disorders, including irritable bowel syndrome (IBS), and is exploring opportunities in the anti-obesity market.
YTD Price Performance: 10.0%
Average Trading Volume: 74,680
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$11.74M
For an in-depth examination of ANR stock, go to TipRanks’ Stock Analysis page.
